Product
CUE-102
1 clinical trial
4 indications
Indication
Colorectal CancerIndication
Stomach CancerIndication
Pancreatic CancerIndication
Ovarian CancerClinical trial
A Phase 1, Open-Label, Dose Escalation and Expansion Study of CUE-102 Monotherapy in HLA-A*0201 Positive Patients With WT1 Positive Recurrent/Metastatic CancersStatus: Recruiting, Estimated PCD: 2024-12-01